15.13  0.08 (0.53%)		09-01 16:00
Open: 14.99 High: 15.305 Volume: 662,395		Pre. Close: 15.05 Low: 14.83 Market Cap: 1,273(M)

Short term
Mid term
Targets	6-month :	20.3	1-year :	22.29
Resists	First :	17.38	Second :	19.09
Pivot price	15.9
Supports	First :	14.61	Second :	12.16
MAs	MA(5) :	15.26	MA(20) :	16.31
	MA(100) :	18.04	MA(250) :	18.53
MACD	MACD :	-0.9	Signal :	-0.9
%K %D	K(14,3) :	10.3	D(3) :	8.3
RSI	RSI(14): 34.4
52-week	High :	62.75	Low :	5.94

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MLTX ] has closed above bottom band by 20.3%. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	15.32 - 15.38	15.38 - 15.45
Low:	14.67 - 14.73	14.73 - 14.81
Close:	15.01 - 15.11	15.11 - 15.23

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Tue, 01 Sep 2026
GOOG: Alphabet Inc - Ordinary Shares - Class C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Tue, 01 Sep 2026
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Thu, 20 Aug 2026
Deep Track Capital, LP Expands MoonLake Immunotherapeutics (MLTX) Stake With 1.59 Million Share Purchase - GuruFocus

Thu, 20 Aug 2026
Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review

Fri, 14 Aug 2026
Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan

Wed, 12 Aug 2026
MoonLake Immunotherapeutics (MLTX) Gets a Buy from BTIG - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	85 (M)
Shares Float	55 (M)
Held by Insiders	8.1 (%)
Held by Institutions	87.5 (%)
Shares Short	5,720 (K)
Shares Short P.Month	6,560 (K)

EPS	-3.84
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.11
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.5 %
Return on Equity (ttm)	-67.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-225 (M)
Levered Free Cash Flow	-132 (M)

PE Ratio	-3.95
PEG Ratio	0
Price to Book value	2.95
Price to Sales	0
Price to Cash Flow	-5.72

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.